Hyloris Pharmaceuticals SA (HYL.BR) Stock

HYL.BR logo

Hyloris Pharmaceuticals SA

HYL.BRBelgium
Healthcare

Company profile

Hyloris Pharmaceuticals SA reported revenue of 7.21 million EUR for fiscal year 2025, down 14.8% from fiscal year 2024, and a net loss of 6.33 million EUR. That is a net profit margin of -87.9% for fiscal year 2025. Our analysis of its filings shows revenue growing from 2.09 million EUR in fiscal year 2023 to 7.21 million EUR in fiscal year 2025, 85.8% a year on average. Hyloris Pharmaceuticals SA reports about 54 full-time employees.

What stands out

  • It reported a net loss in each of its last 5 fiscal years (2021 to 2025).

Figures from company filings; latest fiscal year ended December 31, 2025.

About Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder; XTRAZA and Tranexamic Acid IV RTU for the prevention and treatment of excessive bleeding; HY-094 Iron IV to treat iron deficiency; and Pantoprazole IV for short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis. In addition, the company is involved in the development of Alenura for painful bladder syndrome; Phosphate oral liquid for phosphate supplementation; and HY-095 PPI for the treatment of gastric ulcers in horses. Further, it develops Aspirin IV for acute coronary syndrome indication; Milrinone for late-stage HF with LVAD; Dofetilide IV for atrial fibrillation indication; HY-074 for acute coronary syndrome indication; Metolazone IV for congestive heart failure indication; and HY-75 for coronary heart disease indication. The company has collaboration agreements with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.

Largest shareholders

  • Stijn van Rompay27.65 %27.65%
  • Thomas Jacobsen12.26 %12.26%
  • Bart Versluys7.57 %7.57%
  • Nick Reunbrouck5.75 %5.75%
  • Pieter van Rompay3.27 %3.27%

Share of the company, as of September 25, 2026

Leadership

  • Stijn Van Rompay — Co-Founder, CEO & Director, 49
  • Christophe Marechal — Chief Financial Officer
  • Dietmar Aichhorn Ph.D. — Chief Operating Officer
  • Thomas Jacobsen — Co-Founder, Chief Business Development Officer & Executive Director, 50
  • Ann De Jaeger — Chief Legal Officer & General Secretary, 58

How much revenue does Hyloris Pharmaceuticals SA make?

Hyloris Pharmaceuticals SA reported 7.21 million EUR in revenue for fiscal year 2025, down 14.8% from 8.46 million EUR in fiscal year 2024.

What companies are similar to Hyloris Pharmaceuticals SA?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include UCB SA (UCB.BR).

Has Hyloris Pharmaceuticals SA made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 11.58 million EUR; FY2022, a loss of 11.91 million EUR; FY2023, a loss of 15.38 million EUR; FY2024, a loss of 6.34 million EUR; FY2025, a loss of 6.33 million EUR. It reported a net loss in each of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees54
HeadquartersLiège, Belgium
ExchangeBrussels
TimezoneEurope/Brussels (CET)

Contact & Links

Address
Boulevard Patience et Beaujonc 3/1, Liège, 4000
Phone
32 4 346 02 07
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Hyloris Pharmaceuticals SA (HYL.BR)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/HYL.BR

LinkedInLinkedInXXYouTubeYouTube